Login to Your Account

Cubist's Phase III Squaring Off Against Pain, Constipation

By Randy Osborne
Staff Writer

Friday, July 19, 2013

Cubist Pharmaceuticals Inc. followed up its earnings tally with word that the first patient joined the 1,800-patient Phase III program called ASCENT with bevenopran, previously known as CB-5945, a peripherally active mu opioid receptor antagonist for chronic noncancer pain and opioid-induced constipation.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription